Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1969;41(3):599-606.

Evaluation of influenza virus mutants for possible use in a live virus vaccine

Evaluation of influenza virus mutants for possible use in a live virus vaccine

J Mills et al. Bull World Health Organ. 1969.

Abstract

Two approaches to the attenuation of influenza A2 virus were studied: adaptation to a sub-optimum growth temperature and the production of temperature-sensitive mutants.A strain of A2/Hong Kong/68 virus was adapted to growth at 25 degrees C in calf kidney tissue culture, and a virus suspension was prepared for administration to volunteers after cloning by 2 terminal dilution purifications. The results indicated that the low-temperature-adapted strain had reduced infectivity for man, but was not attenuated since illness occurred when sufficient virus was administered to infect all volunteers.More encouraging results were obtained with 2 temperature-sensitive mutants of influenza A2/1965 virus. One of these mutants was unable to form plaques in calf kidney tissue culture at temperatures above 36 degrees C; the other showed restriction of plaque formation only at 38 degrees C and above. Both mutants were able to infect hamsters, but compared with the wild-type virus there was marked restriction of replication in the lungs. Prior infection of hamsters or mice with either mutant induced significant resistance to subsequent challenge with wild-type influenza A2 virus.

PubMed Disclaimer

References

    1. Nature. 1967 Feb 11;213(5076):612-4 - PubMed
    1. Virology. 1968 May;35(1):41-9 - PubMed
    1. Lancet. 1968 Aug 24;2(7565):418-22 - PubMed
    1. J Immunol. 1969 Mar;102(3):728-32 - PubMed
    1. Prog Med Virol. 1964;6:1-26 - PubMed

Substances

LinkOut - more resources